PTPRC and myeloid sarcoma: To identify patterns in the peripheral blood immune profiles of MS patients, we implemented hierarchical clustering of immune subsets (% of total CD45+ cells) of all samples in both patients (n=27; PPMS=8, RRMS=9, TMS=10, anti-CD20 treated patients excluded) and HD controls (n=10) (Figure 7).